Brainsway Ltd (BWAY) Stock Analysis

Brainsway Ltd (BWAY) is a publicly traded company in the HEALTHCARE sector. It trades at $15.06, carries a market capitalization of $605.55M, a price-to-earnings ratio of 68.59. This page summarizes the public market data, fundamentals, and frequently asked questions for BWAY, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - MEDICAL DEVICES

Exchange: NASDAQ

Key Metrics

Price: $15.06
Market Cap: $605.55M
P/E Ratio: 68.59
EPS: $0.22
52-Week High: $17.35
52-Week Low: $5.68

Market Sentiment

Brainsway Ltd currently has a Neutral sentiment score of -0.02.

About Brainsway Ltd

Brainsway Ltd. is a pioneering medical device company focused on developing non-invasive neuromodulation therapies for neurological and psychiatric disorders. Headquartered in Jerusalem, Israel, the company leverages its proprietary Deep TMS (Transcranial Magnetic Stimulation) technology to address significant unmet medical needs globally. Brainsway's strong commitment to research and development, paired with an innovative approach, positions it as a leader in the neuromodulation sector, driv...

GNG Research Analysis

GNG Research scores Brainsway Ltd (BWAY) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for BWAY.

Frequently Asked Questions

Does BWAY pay dividends?

Brainsway Ltd (BWAY) does not currently pay a regular dividend.

What is BWAY's P/E ratio?

Brainsway Ltd has a price-to-earnings (P/E) ratio of 68.59.

What is BWAY's market cap?

Brainsway Ltd (BWAY) has a market capitalization of $605.55M with a current stock price of $15.06.